Press release
Esophageal Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi,
DelveInsight's, "Esophageal Cancer- Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Esophageal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Esophageal Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Esophageal Cancer treatment therapies, analyzes DelveInsight.
Esophageal Cancer Overview:
Esophageal cancer is a serious and often deadly disease that forms in the esophagus-the tube that carries food from the throat to the stomach. Though not very common, it has a high mortality rate due to frequent late-stage diagnosis. The two primary types are squamous cell carcinoma, which originates in the lining of the esophagus, and adenocarcinoma, which typically arises in the lower esophagus from glandular cells. Early symptoms often mimic milder conditions, leading to delayed detection. Common signs include difficulty swallowing, unexplained weight loss, chest pain, persistent cough, hoarseness, and food regurgitation. In advanced cases, bleeding, anemia, or black stools may occur.
While the exact cause is unclear, known risk factors include chronic GERD, Barrett's esophagus, smoking, excessive alcohol consumption, obesity, and a poor diet. These contribute to genetic mutations and cellular damage that promote tumor growth.
Diagnosis involves a combination of endoscopy, biopsies, and imaging tests like CT, PET scans, and endoscopic ultrasound to confirm cancer and determine its type and spread. Early detection is crucial for better outcomes.
Request for a detailed insights report on Esophageal Cancer pipeline insights [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Esophageal Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Esophageal Cancer Therapeutics Market.
Key Takeaways from the Esophageal Cancer Pipeline Report
*
DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Esophageal Cancer treatment.
*
In January 2025, RNT Health Insights, a health-tech startup based in Chandigarh, received its second Breakthrough Device Designation from the US FDA for its esophageal cancer detection tool. This AI-powered tool assists gastroenterologists in identifying both early and advanced stages of esophageal cancer during white-light upper GI endoscopy procedures.
*
Key Esophageal Cancer companies such as OncoTherapy Science, Inc., Shionogi & Co., Oncolys BioPharma Inc., Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech, NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics, and others are evaluating new drugs for Esophageal Cancer to improve the treatment landscape.
*
Promising Esophageal Cancer pipeline therapies in various stages of development include S-588410, Telomelysin, LVGN-6051, AN-0025, and others.
Esophageal Cancer Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Esophageal Cancer Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Esophageal Cancer market.
Download our free sample page report on Esophageal Cancer pipeline insights [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Esophageal Cancer Emerging Drugs
*
S-588410: OncoTherapy Science, Inc. /Shionogi & Co.
*
Telomelysin: Oncolys BioPharma Inc
*
LVGN-6051: Lyvgen Biopharma
*
AN-0025: Adlai Nortye Biopharma
Esophageal Cancer Companies
More than 80 major companies are actively developing treatments for esophageal cancer. Among them, OncoTherapy Science, Inc. and Shionogi & Co. have drug candidates that are currently in the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 100+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Esophageal Cancer Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Esophageal Cancer Therapies and Key Companies: Esophageal Cancer Clinical Trials and advancements [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Esophageal Cancer Pipeline Therapeutic Assessment
- Esophageal Cancer Assessment by Product Type
- Esophageal Cancer By Stage
- Esophageal Cancer Assessment by Route of Administration
- Esophageal Cancer Assessment by Molecule Type
Download Esophageal Cancer Sample report to know in detail about the Esophageal Cancer treatment market @ Esophageal Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Esophageal Cancer Current Treatment Patterns
4. Esophageal Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Esophageal Cancer Late-Stage Products (Phase-III)
7. Esophageal Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Esophageal Cancer Discontinued Products
13. Esophageal Cancer Product Profiles
14. Esophageal Cancer Key Companies
15. Esophageal Cancer Key Products
16. Dormant and Discontinued Products
17. Esophageal Cancer Unmet Needs
18. Esophageal Cancer Future Perspectives
19. Esophageal Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Esophageal Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-miltenyi-biomedicine-adicet-bio-velosbio-novartis-pharmaceuticals-sanofi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, here
News-ID: 4106964 • Views: …
More Releases from ABNewswire

Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…

Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…

Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…

A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Esophageal
Rising Prevalence Of Chronic Esophageal Disorders Boosts The Esophageal Catheter …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Esophageal Catheters Market Size By 2025?
The market for esophageal catheters has experienced significant expansion recently. Its growth is projected to continue from a market size of $2.43 billion in 2024 to an increased value of $2.64 billion in 2025, reflecting a compound annual growth…
Evolving Market Trends In The Esophageal Dilator Industry: Advanced Solutions En …
The Esophageal Dilator Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dilator Market Size During the Forecast Period?
The esophageal dilator market size will grow from $1.49 billion in 2024 to $1.57 billion in 2025 at a CAGR of 5.2%. Growth…
Evolving Market Trends In The Esophageal Dysphagia Industry: Innovative Technolo …
The Esophageal Dysphagia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Esophageal Dysphagia Market Size During the Forecast Period?
The market size for esophageal dysphagia has seen robust growth in the past few years. Projections show that it is set to expand…
Key Trend Reshaping the Esophageal Dilator Market in 2025: Advanced Solutions En …
What combination of drivers is leading to accelerated growth in the esophageal dilator market?
The esophageal dilator market is expected to see growth driven by the increasing occurrence of esophageal disorders. These disorders refer to a range of conditions affecting the esophagus, responsible for transporting food and fluids from the mouth to the stomach. The escalated prevalence of such disorders can be linked to factors such as the growing instances of…
Advanced Solutions Enhanced Esophageal Dilator Market Trend: A Crucial Influence …
What Is the Expected Size and Growth Rate of the Esophageal Dilator Market?
The market size for esophageal dilators has experienced robust growth in the past few years. The market's value, estimated at $1.49 billion in 2024, is predicted to inflate to $1.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. This positive trend during the historical period is primarily driven by factors such as an increase…
Top Factor Driving Esophageal Catheters Market Growth in 2025: Rising Prevalence …
How Big Is the Esophageal Catheters Market Expected to Be, and What Will Its Growth Rate Be?
The esophageal catheters market has experienced significant growth in recent years. It will grow from $2.43 billion in 2024 to $2.64 billion in 2025, at a CAGR of 8.6%. The growth can be attributed to advancements in critical care, the rise of cardiac and respiratory disorders, the use of minimally invasive procedures, and developments…